TG Therapeutics Investigational Trial Site

Nashville, Tennessee 37215

1 studies enrolling now · 9 studies all time

What they study most

Aggressive Lymphoma, CLL, Chronic Lymphocytic Leukemia, DLBCL, Follicular Lymphoma, Indolent Lymphoma, MCL, Marginal Zone Lymphoma, Mediastinal Large B-cell Lymphoma, Multiple Sclerosis, Non Hodgkin Lymphoma, Relapsing Multiple Sclerosis

Studies at this site

• A Study Evaluating the Real World Experience of Participants Treated With BRIUMVI® (Ublituximab-xiiy) for Relapsing Multiple Sclerosis (RMS) — Recruiting now
• Ublituximab + TGR-1202 Compared to Obinutuzumab + Chlorambucil in Participants With Untreated and Previously Treated Chronic Lymphocytic Leukemia — Stopped early
• Study of TG-1801 Alone or in Combination With Ublituximab in Subjects With B-Cell Lymphoma or Chronic Lymphocytic Leukemia — Stopped early
• Evaluate the Efficacy and Safety of TGR-1202 in Participants With Chronic Lymphocytic Leukemia Who Are Intolerant to Prior Therapy — Stopped early
• Study to Assess the Efficacy and Safety of Ublituximab in Combination With Umbralisib and Venetoclax Compared to Ublituximab in Combination With Umbralisib in Subjects With CLL (ULTRA-V) — Stopped early
• Study to Assess Umbralisib Plus Ublituximab in Participants With Treatment Naïve Follicular Lymphoma — Stopped early
• A Study to Evaluate the Safety and Efficacy of Ublituximab in Combination With Umbralisib for Participants Previously Enrolled in Protocol UTX-TGR-304 — Stopped early
• Extension Trial of Ublituximab and TGR-1202 in Combination or as Single Agents in Subjects Currently Receiving Treatment on Ublituximab and/or TGR-1202 Trials — Stopped early
• Ublituximab in Combination With Ibrutinib Versus Ibrutinib Alone in Participants With Previously Treated High-Risk Chronic Lymphocytic Leukemia (CLL) — Completed